{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04602104",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MEXARDS"
      },
      "Organization": {
        "OrgFullName": "Ruijin Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS",
      "OfficialTitle": "A Multiple, Randomized, Double-blinded, Controlled Clinical Study of Allogeneic Human Mesenchymal Stem Cell Exosomes (hMSC-Exos) Nebulized Inhalation in the Treatment of Acute Respiratory Distress Syndrome"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 30, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 25, 2020",
      "StudyFirstSubmitQCDate": "October 20, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 26, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 1, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 2, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Ruijin Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Cellular Biomedicine Group Ltd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of acute respiratory distress syndrome (ARDS)",
      "DetailedDescription": "According to the 2012 Berlin diagnostic criteria, there are currently more than 3 million ARDS patients worldwide, accounting for about 10% of patients in the intensive care unit (ICU). In recent years, the incidence of ARDS has increased significantly, which has significantly increased the social and economic burden. The impact of ARDS can even be compared with tumors, AIDS or myocardial infarction. There are the basic clinical treatments, such as using various ventilation methods to improve hypoxia and choosing alternative therapies to improve renal insufficiency. Therefore, there is still a lack of specific treatment measures.\n\nExosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers with the abundance of adhesive proteins that readily interact with cellular membranes. Studies have confirmed that MSC-Exos can improve most of the pathological changes caused by lung infection, reduce pulmonary edema, reduce protein exudation, reduce alveolar inflammation, and clear bacterial infections. Thus, it brings new hope for the treatment of ARDS.\n\nThe purpose of this study is to evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of acute respiratory distress syndrome (ARDS)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Respiratory Distress Syndrome"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "human mesenchymal stem cell exosomes"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "169",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Phase 1: hMSC-Exos low dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "hMSC-Exos low-dose group",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: low dose hMSC-Exos"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 1: hMSC-Exos medium dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "hMSC-Exos medium-dose group",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: medium dose hMSC-Exos"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 1: hMSC-Exos high dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "hMSC-Exos high-dose group",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: high dose hMSC-Exos"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2: hMSC-Exos dosage 1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "basic treatment+hMSC-Exos (a quarter of MTD/day)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Dosage 1of hMSC-Exos"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2: hMSC-Exos dosage 2",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "basic treatment+hMSC-Exos (MTD/day)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Dosage 2 of hMSC-Exos"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2: control group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "basic treatment+normal saline",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: No hMSC-derived exosomes"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "low dose hMSC-Exos",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 1: hMSC-Exos low dose"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "medium dose hMSC-Exos",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 1: hMSC-Exos medium dose"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "high dose hMSC-Exos",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0*10^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 1: hMSC-Exos high dose"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Dosage 1of hMSC-Exos",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 2: hMSC-Exos dosage 1"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Dosage 2 of hMSC-Exos",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 2: hMSC-Exos dosage 2"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "No hMSC-derived exosomes",
            "InterventionDescription": "basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 2: control group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of adverse reaction",
            "PrimaryOutcomeDescription": "Incidence of adverse reaction",
            "PrimaryOutcomeTimeFrame": "up to 14 days"
          },
          {
            "PrimaryOutcomeMeasure": "TTCI",
            "PrimaryOutcomeDescription": "Time to Clinical improvement",
            "PrimaryOutcomeTimeFrame": "up to 28 days"
          },
          {
            "PrimaryOutcomeMeasure": "28-day mortality",
            "PrimaryOutcomeDescription": "28-day mortality",
            "PrimaryOutcomeTimeFrame": "up to 28 days"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Murray lung injury score",
            "SecondaryOutcomeDescription": "The minimum value is 0 and the maximum are 16. Higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60"
          },
          {
            "SecondaryOutcomeMeasure": "PaO2/FiO2",
            "SecondaryOutcomeDescription": "oxygen index: the ratio of alveolar oxygen partial pressure to fraction of inspired oxygen",
            "SecondaryOutcomeTimeFrame": "baseline and Day 3, Day7, Day14, Day28, Day60"
          },
          {
            "SecondaryOutcomeMeasure": "SOFA score",
            "SecondaryOutcomeDescription": "The minimum value is 0 and the maximum are 48. Higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60"
          },
          {
            "SecondaryOutcomeMeasure": "ApachⅡ score",
            "SecondaryOutcomeDescription": "The minimum value is 0 and the maximum are 24. Higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "baseline and Day 1, Day 2, Day 3, Day 4, Day 5, Day6, Day7, Day14, Day28, Day60"
          },
          {
            "SecondaryOutcomeMeasure": "The number of days the survivor was in ICU",
            "SecondaryOutcomeDescription": "The number of days the survivor was in ICU",
            "SecondaryOutcomeTimeFrame": "up to 60 days"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nThe subjects themselves or their family members voluntarily participate in this study and sign the informed consent form;\n18-70 years old, male or female;\nDefinitely diagnosed as acute respiratory distress syndrome (ARDS) (according to the Berlin definition and diagnostic criteria of ARDS);\nCourse of disease <96 hours after diagnosis;\nChest X-ray showed bilateral infiltration with pulmonary edema; no clinical manifestations of left ventricular hypertension, or pulmonary artery wedge pressure (PAOP) ≤18mmHg.\n\nExclusion Criteria:\n\nPatients with severe allergic constitution;\nModerate to severe liver failure (children Pugh score > 12);\nPatients with severe chronic respiratory diseases, PaCO2 > 50mmhg, and need home oxygen therapy;\nSevere trauma occurred within 14 days before screening;\nHistory of malignant tumor (patients with skin basal cell carcinoma in the past can be included);\nThey are undergoing hemodialysis or peritoneal dialysis;\nThe patients who had deep venous thrombosis or pulmonary embolism within 90 days;\nAcute myocardial infarction occurred within 30 days;\nNeuromuscular diseases that result in impaired natural ventilation include, but are not limited to, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, Guillain Barre syndrome, and myasthenia gravis;\nObesity (BMI > 28);\nLung transplantation;\nBone marrow transplantation;\nActive immunosuppression is defined as receiving immunosuppressive drugs or having a medical condition associated with immunodeficiency. These included: 1) HIV (AIDS or CD4 < 200 cells / mm3); 2) chemotherapy within 6 weeks before randomization; 3) immunosuppressive therapy, including maintenance glucocorticoid therapy (> 40) Results: 1) short term systemic steroid therapy (intravenous or oral) for less than 1 week, topical steroid for skin diseases; 4) absolute neutrophil count < 500 / mm3;\nPatients undergoing extracorporeal circulation support (ECMO) or high frequency oscillatory ventilation;\nThey were not willing to receive lung protective ventilation (minimum tidal volume 6ml / kg pbw) or liquid management treatment;\nHave a history of epilepsy, need continuous anticonvulsant therapy, or have received anticonvulsant therapy in the past 3 years;\nThe estimated survival time was less than 30 days;\nHepatitis B, hepatitis C, AIDS, syphilis patients;\nWomen of childbearing age are pregnant, lactating or pregnant within one year;\nThose who could not understand the study protocol;\nAccording to the judgment of the researchers, there were other situations in which the patients were not suitable to participate in the study (for example, there were factors to reduce the follow-up compliance, and the patients did not receive relevant supportive treatment, etc.).",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jieming Qu, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-21-64370045",
            "CentralContactEMail": "jmqu0906@163.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Ruijin Hospital, Medical School of Shanghai Jiaotong University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Shanghai",
            "LocationState": "Shanghai",
            "LocationZip": "200025",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jieming Qu, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-21-64370045",
                  "LocationContactEMail": "jmqu0906@163.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No",
      "IPDSharingDescription": "No plan to make individual participant data (IPD) available to other researchers"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000012128",
            "ConditionMeshTerm": "Respiratory Distress Syndrome"
          },
          {
            "ConditionMeshId": "D000012127",
            "ConditionMeshTerm": "Respiratory Distress Syndrome, Newborn"
          },
          {
            "ConditionMeshId": "D000055371",
            "ConditionMeshTerm": "Acute Lung Injury"
          },
          {
            "ConditionMeshId": "D000013577",
            "ConditionMeshTerm": "Syndrome"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000004194",
            "ConditionAncestorTerm": "Disease"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000012120",
            "ConditionAncestorTerm": "Respiration Disorders"
          },
          {
            "ConditionAncestorId": "D000007235",
            "ConditionAncestorTerm": "Infant, Premature, Diseases"
          },
          {
            "ConditionAncestorId": "D000007232",
            "ConditionAncestorTerm": "Infant, Newborn, Diseases"
          },
          {
            "ConditionAncestorId": "D000055370",
            "ConditionAncestorTerm": "Lung Injury"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafAsFound": "Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26290",
            "ConditionBrowseLeafName": "Respiratory Aspiration",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14117",
            "ConditionBrowseLeafName": "Respiratory Distress Syndrome",
            "ConditionBrowseLeafAsFound": "Respiratory Distress Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14116",
            "ConditionBrowseLeafName": "Respiratory Distress Syndrome, Newborn",
            "ConditionBrowseLeafAsFound": "Respiratory Distress Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27297",
            "ConditionBrowseLeafName": "Acute Lung Injury",
            "ConditionBrowseLeafAsFound": "Acute Respiratory Distress Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27296",
            "ConditionBrowseLeafName": "Lung Injury",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14109",
            "ConditionBrowseLeafName": "Respiration Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25022",
            "ConditionBrowseLeafName": "Premature Birth",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9431",
            "ConditionBrowseLeafName": "Infant, Premature, Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9428",
            "ConditionBrowseLeafName": "Infant, Newborn, Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4927",
            "ConditionBrowseLeafName": "Respiratory Distress Syndrome, Infant",
            "ConditionBrowseLeafAsFound": "Respiratory Distress Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T192",
            "ConditionBrowseLeafName": "Acute Respiratory Distress Syndrome",
            "ConditionBrowseLeafAsFound": "Acute Respiratory Distress Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}